Pacific Biosciences of California (NAS:PACB) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Pacific Biosciences of California Cash Conversion Cycle Related Terms
Pacific Biosciences of California Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Cash Conversion Cycle Chart
PACB vs CATX, LAB, KIDS: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Cash Conversion Cycle falls into.
Pacific Biosciences of California Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Cash Conversion Cycle of 203.12 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Cash Conversion Cycle too high?
Pacific Biosciences of California's current Cash Conversion Cycle is 203.12. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Pacific Biosciences of California's value of 203.12 is 29.4% above this industry median. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Cash Conversion Cycle compare to CATX and LAB?
Pacific Biosciences of California's Cash Conversion Cycle of 203.12 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Pacific Biosciences of California's value of 203.12 is 29.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Cash Conversion Cycle of 203.12 is 29.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Cash Conversion Cycle is 203.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.65 — trading 1.9% above its estimated fair value. The current Cash Conversion Cycle is 203.12 and 29.4% above the Medical Devices & Instruments industry median of 156.96. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Cash Conversion Cycle is 203.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued.
The current stock price of $1.65 is trading 1.9% above its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Cash Conversion Cycle: 203.12
GF Value™: $1.62 vs. price of $1.65 (1.9% above fair value)
Industry Position: 29.4% above the Medical Devices & Instruments median
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
